These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 30624566)

  • 1. Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes.
    Lee SG; Lee HJ; Yoon MS; Kim DH
    JAMA Dermatol; 2019 Feb; 155(2):172-177. PubMed ID: 30624566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.
    Kridin K; Bergman R
    JAMA Dermatol; 2018 Oct; 154(10):1152-1158. PubMed ID: 30090931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
    Benzaquen M; Borradori L; Berbis P; Cazzaniga S; Valero R; Richard MA; Feldmeyer L
    J Am Acad Dermatol; 2018 Jun; 78(6):1090-1096. PubMed ID: 29274348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Risk of Bullous Pemphigoid With Initiation of Dipeptidyl Peptidase-4 Inhibitor vs Second-generation Sulfonylurea.
    Lee H; Chung HJ; Pawar A; Patorno E; Kim DH
    JAMA Dermatol; 2020 Oct; 156(10):1107-1114. PubMed ID: 32697283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
    Hung CT; Liu JS; Cheng CY; Chung CH; Chiang CP; Chien WC; Wang WM
    J Dermatol; 2020 Mar; 47(3):245-250. PubMed ID: 31885117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
    Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
    J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
    Sugiyama S; Yamamoto T; Aoyama Y
    J Dermatol; 2022 Jul; 49(7):697-702. PubMed ID: 35478414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between dipeptidyl peptidase-4 inhibitors and increased risk for bullous pemphigoid within 3 months from first use: A 5-year population-based cohort study using the Japanese National Database.
    Kuwata H; Nishioka Y; Noda T; Kubo S; Myojin T; Higashino T; Takahashi Y; Ishii H; Imamura T
    J Diabetes Investig; 2022 Mar; 13(3):460-467. PubMed ID: 34559464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.
    Béné J; Moulis G; Bennani I; Auffret M; Coupe P; Babai S; Hillaire-Buys D; Micallef J; Gautier S;
    Br J Dermatol; 2016 Aug; 175(2):296-301. PubMed ID: 27031194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid.
    Chijiwa C; Takeoka S; Kamata M; Tateishi M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Watanabe S; Tada Y
    J Dermatol; 2018 May; 45(5):596-599. PubMed ID: 29411416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
    Jedlowski PM; Jedlowski MF; Fazel MT
    Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®.
    Carnovale C; Mazhar F; Arzenton E; Moretti U; Pozzi M; Mosini G; Leoni O; Scatigna M; Clementi E; Radice S
    Expert Opin Drug Saf; 2019 Nov; 18(11):1099-1108. PubMed ID: 31519110
    [No Abstract]   [Full Text] [Related]  

  • 13. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: A systematic review and adjusted meta-analysis.
    Phan K; Charlton O; Smith SD
    Australas J Dermatol; 2020 Feb; 61(1):e15-e21. PubMed ID: 31215644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors.
    Izumi K; Nishie W; Beniko M; Shimizu H
    Front Immunol; 2019; 10():1439. PubMed ID: 31297116
    [No Abstract]   [Full Text] [Related]  

  • 15. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes.
    Douros A; Rouette J; Yin H; Yu OHY; Filion KB; Azoulay L
    Diabetes Care; 2019 Aug; 42(8):1496-1503. PubMed ID: 31182489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01.
    Hibi A; Kasahara Y; Ishihara Y; Hata K; Hosokawa N; Nakagawa T
    CEN Case Rep; 2020 Aug; 9(3):189-194. PubMed ID: 31993957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors].
    Kodera R; Chiba Y; Tamura Y; Miyazawa R; Tanei R; Mori S; Ito H; Araki A
    Nihon Ronen Igakkai Zasshi; 2019; 56(1):43-50. PubMed ID: 30760682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients.
    Kawaguchi Y; Shimauchi R; Nishibori N; Kawashima K; Oshitani S; Fujiya A; Shibata T; Ohashi N; Izumi K; Nishie W; Shimizu H; Arima H; Sobajima H
    J Diabetes Investig; 2019 Mar; 10(2):392-398. PubMed ID: 29920976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
    Iwamoto Y; Anno T; Koyama K; Kawasaki F; Kaku K; Tomoda K; Sugiyama S; Aoyama Y; Kaneto H
    Front Immunol; 2022; 13():843480. PubMed ID: 35309321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study.
    Lambadiari V; Kountouri A; Kousathana F; Korakas E; Kokkalis G; Theotokoglou S; Palaiodimou L; Katsimbri P; Ikonomidis I; Theodoropoulos K; Papadavid E
    BMC Endocr Disord; 2021 Feb; 21(1):23. PubMed ID: 33573656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.